Tarsus (TARS) director Wendy Yarno receives RSU and option grants as board pay
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Tarsus Pharmaceuticals director Wendy L. Yarno received new equity awards as part of her non-employee director compensation for the company’s 2026 annual meeting. She was granted 1,209 and 2,417 restricted stock units, each RSU equal to one common share, plus an option for 3,837 shares at an exercise price of $64.34. The option vests in full one year after grant, while the RSUs vest either fully after one year or in four scheduled installments, all subject to continued board service. These are compensation grants, not open-market share purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
YARNO WENDY L
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 3,837 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 2,417 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 1,209 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 3,837 shares (Direct, null);
Restricted Stock Units — 2,417 shares (Direct, null)
Footnotes (1)
- Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.
Key Figures
RSU grant 1: 1,209 units
RSU grant 2: 2,417 units
Stock option shares: 3,837 shares
+2 more
5 metrics
RSU grant 1
1,209 units
Restricted Stock Units tied to 2026 annual meeting service
RSU grant 2
2,417 units
Restricted Stock Units vesting in four scheduled installments
Stock option shares
3,837 shares
Annual non-employee director option grant
Option exercise price
$64.34 per share
Exercise price for 3,837-share stock option grant
Option expiration
June 24, 2036
Expiration date of the granted stock option
Key Terms
Restricted Stock Unit, RSU, Stock Option (right to buy), non-employee director, +1 more
5 terms
Restricted Stock Unit financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
RSU financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an expiration date of 2036-06-24"
non-employee director financial
"granted in connection with the Reporting Person's service as a non-employee director"
annual meeting of stockholders financial
"as of the Company's 2026 annual meeting of stockholders"
FAQ
What did Tarsus (TARS) director Wendy L. Yarno report on this Form 4?
Director Wendy L. Yarno reported equity compensation grants, not market trades. She received restricted stock units and a stock option tied to her service as a non-employee director following Tarsus Pharmaceuticals’ 2026 annual meeting of stockholders.
How many restricted stock units did Wendy L. Yarno receive from Tarsus (TARS)?
She received two RSU grants: 1,209 units and 2,417 units. Each restricted stock unit represents a contingent right to receive one share of Tarsus Pharmaceuticals common stock if the applicable vesting conditions tied to board service are satisfied.
What stock option grant did Wendy L. Yarno receive from Tarsus (TARS)?
She was granted a stock option covering 3,837 shares of Tarsus Pharmaceuticals common stock at an exercise price of $64.34. The option was issued as her annual non-employee director option grant for 2026, with vesting based on continued board service.
When do Wendy L. Yarno’s Tarsus (TARS) stock option and RSUs vest?
The annual option vests in full on the one-year anniversary of the grant date. One RSU grant vests fully after one year, while the other vests in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, all requiring continued service.
Do Wendy L. Yarno’s reported Tarsus (TARS) transactions involve open-market buying or selling?
No, the Form 4 reflects equity awards granted as compensation. The transactions are coded as grants (Code A) of restricted stock units and a stock option, not open-market purchases or sales of Tarsus Pharmaceuticals common stock.
What does each RSU granted to Wendy L. Yarno by Tarsus (TARS) represent?
Each restricted stock unit represents a contingent right to receive one share of Tarsus Pharmaceuticals common stock. Delivery of the underlying shares depends on satisfaction of vesting conditions tied to Wendy L. Yarno’s ongoing service as a non-employee director.